Group 1 - Public funds have actively participated in the A-share private placement market, with a total allocation amount of 9.785 billion yuan and a floating profit of 1.694 billion yuan, resulting in an overall floating profit ratio of 17.32% as of May 20, 2025 [1][3] - The top-performing public fund is Yimi Fund, achieving a floating profit ratio of 49.49% with a floating profit of 39.588 million yuan from an allocation of 80 million yuan [1][3] - Companies like Leshan Power and Sheng Tai Co. have shown significant floating profits, with Leshan Power leading at a floating profit ratio of 178% [3][4] Group 2 - Private funds have also shown strong performance, with 27 private institutions participating in 23 A-share companies, achieving a total allocation of 1.943 billion yuan and a floating profit of 528 million yuan, resulting in a floating profit ratio of 27.19% as of May 21, 2025 [2][6] - Small-scale private funds have excelled, with Lihua Investment achieving a floating profit ratio of 178.04% from a single allocation of 810,000 yuan [7][8] - The overall performance of the private placement market indicates a trend towards higher returns in sectors such as new energy, semiconductors, and high-end manufacturing, which account for over 70% of the high floating profit ratios [9]

Investment Rating - The report maintains an "Accumulate" investment rating for the company [3]. Core Views - The company is a leading player in the domestic ophthalmic medical device industry, focusing on innovation, particularly in intraocular lenses and orthokeratology lenses. The business is expected to gradually recover from the impact of centralized procurement, with the launch of the dual-focus intraocular lens contributing to revenue growth [1][6]. - The company has received special approval from the National Medical Products Administration for its refractive intraocular lens, which is anticipated to facilitate domestic substitution and enhance performance [1][6]. - Revenue projections for the company are optimistic, with expected revenues of 1.734 billion yuan in 2025, representing a 23% year-on-year growth, and net profit expected to reach 465 million yuan, also reflecting a 20% increase [2][6]. Financial Data and Valuation - The company’s total revenue is projected to grow from 951 million yuan in 2023 to 2.56 billion yuan in 2027, with year-on-year growth rates of 64%, 48%, 23%, 22%, and 21% respectively [2][8]. - Operating profit is expected to increase from 327 million yuan in 2023 to 750 million yuan in 2027, with growth rates of 26%, 32%, 20%, 21%, and 19% [2][8]. - The earnings per share (EPS) is projected to rise from 1.57 yuan in 2023 to 3.49 yuan in 2027, with a corresponding decrease in the price-to-earnings (PE) ratio from 49.5 to 22.3 over the same period [2][8]. Market Performance - The current stock price is 77.91 yuan, with a total market capitalization of 15 billion yuan [3]. - The company has experienced a decline in stock performance, with absolute performance down by 25% over the past month and six months, and down 11% over the past year [5]. Shareholder Information - The major shareholder is Xie Jiangbing, holding a 12.68% stake in the company [3].

股票代码：688050 股票简称：爱博医疗 爱博诺德（北京）医疗科技股份有限公司 （北京市昌平区科技园区兴昌路 9 号） 2024 年度以简易程序向特定对象发行股票 上市公告书 保荐机构（主承销商） （北京市丰台区西营街 8 号院 1 号楼青海金融大厦） 二〇二五年五月 特别提示 一、发行股票数量及价格 1、发行股票数量：3,593,615 股 2、发行股票价格：79.20 元/股 3、募集资金总额：人民币 284,614,308.00 元 本次发行新增股份将于限售期届满后的次一交易日起在上海证券交易所科 创板上市流通交易，如遇法定节假日或休息日，则顺延至其后的第一个交易日。 三、发行对象限售期安排 本次发行的股票，自本次发行结束之日起六个月内不得转让。本次发行结束 后，因公司送红股、资本公积金转增等原因增加的公司股份亦应遵守上述限售期 安排。如相关法律、法规和规范性文件对限售期要求有变更的，则限售期根据变 更后的法律、法规和规范性文件要求进行相应调整。 限售期届满后按中国证监会及上交所的有关规定执行。 4、募集资金净额：人民币 280,612,310.30 元 1 | 四、董事、监事和高级管理人员持股变动情 ...

爱博医疗公告，公司2024年度以简易程序向特定对象发行股票数量为359.36万股，发行价格为79.2元/ 股，募集资金总额为2.85亿元，募集资金净额为2.81亿元。本次发行新增股份已于2025年5月12日在中国 证券登记结算有限责任公司上海分公司办理完毕股份登记手续，预计上市时间为限售期届满后的次一交 易日。本次发行不会导致公司控制权发生变化，控股股东及实际控制人仍为解江冰。 ...

2025.05. 11 本文字数：2500，阅读时长大约4分钟 作者 | 第一财经 曹璐 美国"对等关税"政策发酵，全球贸易格局继续调整，成为资本市场近期关注的焦点。Wind数据显 示，截至5月9日，近一个月来机构调研热度飙升，2210家上市公司迎来3068次调研，以区间18个交 易日计算，平均每天有超过170次调研。 这轮调研热潮中，电子、机械设备、医药生物等三大板块成为机构重点关注的领域。立讯精密 （002475.SZ）、水晶光电（002273.SZ）等公司吸引超300家机构扎堆调研。此外，机构投资者在关 注企业财报业绩的同时，也重点聚焦了关税冲击下的海外布局、成本转嫁策略等关键问题。 "财报季后和增量政策空窗期，仍建议关注具有产业进展的科技方向。"金鹰基金权益研究部金达莱对 第一财经表示，AI应用、人形机器人、智能驾驶等新质生产力方向近期已有所反弹，随着财报落 地，AI大模型产业进展或带动其再度有所表现，日历效应下利于节后资金回流和科技成长风格的估 值修复。 近一个月3068次调研 针对关税影响问题，该公司在调研中表示，目前市场上更多的是情绪上的恐慌，但从企业实际经营的 角度来看，大多数出口美国的终端产 ...

Company Overview - Aibo Medical closed at 81.07 yuan, up 1.58%, with a rolling PE ratio of 40.65 times and a total market value of 15.366 billion yuan [1] - The company ranks 83rd in the medical device industry, which has an average PE ratio of 49.02 times and a median of 36.25 times [1] Shareholder Information - As of March 31, 2025, Aibo Medical had 9,729 shareholders, a decrease of 94 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Aibo Medical focuses on the independent research, production, sales, and related services of ophthalmic medical devices, with main products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] Financial Performance - In the first quarter of 2025, Aibo Medical reported revenue of 357 million yuan, a year-on-year increase of 15.07%, and a net profit of 92.5581 million yuan, a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]

股票代码：688050 股票简称：爱博医疗 爱博诺德（北京）医疗科技股份有限公司 （北京市昌平区科技园区兴昌路 9 号） 2024 年度以简易程序向特定对象发行股票 发行情况报告书 保荐机构（主承销商） （北京市丰台区西营街 8 号院 1 号楼青海金融大厦） 二〇二五年四月 发行人全体董事、监事、高级管理人员声明 本公司及全体董事、监事、高级管理人员承诺本发行情况报告书不存在虚假 记载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律 责任。 全体董事签名： 解江冰 王韶华 王 曌 陈 勇 Yu Fang 王海燕 冷新宇 姜 峰 魏永吉 全体监事签名： 王丹璇 张 敏 王玉娇 除董事外的高级管理人员签名： 爱博诺德（北京）医疗科技股份有限公司 年 月 日 1 贾宝山 郭彦昌 周裕茜 3 2 4 5 2024 年 5 月 8 日，公司 2023 年年度股东大会审议通过《关于提请股东大会 授权董事会以简易程序向特定对象发行股票相关事宜的议案》，就本次发行证券 种类和面值、发行方式及发行时间、发行对象及向原股东配售的安排、定价基准 日、发行价格及定价原则、募集资金用途、决议的有效期等发行相关事宜予以 ...

上海市方达律师事务所 关于爱博诺德（北京）医疗科技股份有限公司 以简易程序向特定对象发行股票之 发行过程及认购对象合规性的 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于爱博诺德（北京）医疗科技股份有限公司 以简易程序向特定对象发行股票之发行过程及认购对象合规性的 法律意见书 二〇二五年四月 FANGDA PARTNERS http://www.fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 法律意见书 致：爱博诺德（北京）医疗科技股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律执 业资格的律师事务所。根据爱博诺德（北京）医疗科技股份有限公司（以下简称"发 行人"、"爱博医疗"或"公司"）与本所签 ...